jonjones: very much appreciate your assessment here. I am familiar w/other industries where the patent is actually granted for the process of how something is done/manufactured. For example, the planar process was patented and every company that made any diffused semiconductor device had to pay royalties to Fairchild (this went on for decades). The process becomes the product in such cases. In the case w/AVXL if they collaborated w/Cognision ,as the patent application suggests, and a service for diagnosing and treating (W/A2-73) was performed then one could imagine AD/CNS clinics world wide following the diagnostic process using the tools and dosing/treating. They would pay royalties to both. So, in that scenario then not only is A2-73 a saleable product but so is the diagnostic/treatment service, clinics will love us. Not clear how Cognision would work it though, unless they did the same thing w/another Bio supplier. In that case the lawyers would have full time employment, IMO.
Market Data 
Markets 
AI
